<SEC-DOCUMENT>0001193125-12-069073.txt : 20120221
<SEC-HEADER>0001193125-12-069073.hdr.sgml : 20120220
<ACCEPTANCE-DATETIME>20120221070041
ACCESSION NUMBER:		0001193125-12-069073
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120221
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120221
DATE AS OF CHANGE:		20120221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		12624864

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d304783d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): February&nbsp;21, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registration as specified in charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02453</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report.)
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02. Results of Operations and Financial Condition. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;21, 2012, Repligen Corporation announced its preliminary financial results for quarter and nine-month fiscal year ended December&nbsp;31,
2011. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information in this Form 8-K and the exhibit attached hereto shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated February&nbsp;21, 2012. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: February&nbsp;21, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Walter C. Herlihy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Walter C. Herlihy</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated February 21, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d304783dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>


<TR>
<TD VALIGN="top">


<IMG SRC="g304783ex99_1pg01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 Seyon Street</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite
100</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham,&nbsp;Massachusetts&nbsp;02453</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">781-250-0111</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">781-250-0115</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura L. Whitehouse </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">VP, Market Development </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781) 419-1812 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December&nbsp;31, 2011
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call Today 10 a.m. EST </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; February&nbsp;21, 2012</B> &#150; Repligen Corporation (NASDAQ: RGEN) today reported preliminary financial results for the quarter and nine-month fiscal period ended
December&nbsp;31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December&nbsp;20, 2011 and the successful filing of the
Company&#146;s first new drug application (NDA) for SecreFlo&#153; on December&nbsp;21, 2011. These preliminary results include estimates of the results of operations from December 21-31, 2011 for our new subsidiary Repligen Sweden AB (previously
Novozymes Biopharma Sweden AB), but excludes any purchase accounting adjustments associated with the acquisition. The Company was able to acquire the net assets of Novozymes Biopharma Sweden AB at a purchase price significantly below the fair market
value of the acquired net assets and thus the Company anticipates recording a gain on bargain purchase once purchase accounting is completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue for the quarter ended December&nbsp;31, 2011 is expected to be approximately $7.2 million compared to total revenue of $7.1 million for the
quarter ended December&nbsp;31, 2010. Bioprocessing product revenue for the quarter ended December&nbsp;31, 2011 is anticipated to be $3.1 million, the same as bioprocessing revenue for the quarter ended December&nbsp;31, 2010. Royalty and research
revenue for the quarter ended December&nbsp;31, 2011 is expected to be approximately $4.1 million compared to $3.9 million for the quarter ended December&nbsp;31, 2010. Repligen Sweden AB did not record material revenues during the post-acquisition
period as the transaction closed just prior to year end. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses for the quarter ended December&nbsp;31, 2011 are expected to be
in the range of $9.2 to $9.7 million compared to operating expenses of $6.8 million for the quarter ended December&nbsp;31, 2010. Net loss for the quarter ended December&nbsp;31, 2011, before accounting for any potential gain on acquisition, is
expected to be in the range of $2.0 to $2.5 million, compared to net income of $376,000 for the quarter ended December&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net
loss and the increase in operating expenses were the result of $2.7 million of one-time expenditures including approximately $1.7 million of transaction costs and $0.5 million of operating costs related to the acquisition of Repligen Sweden AB, an
acquisition that is expected to more than double product revenue in 2012. In addition, the Company incurred $0.5 million related to the filing of a new drug application (NDA) for SecreFlo&#153;, a pancreatic imaging agent that is currently under
review by the FDA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended
Dec. 31, 2011 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I> Page
 2
 of 5 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the nine-month fiscal period ended December&nbsp;31, 2011, total revenue is expected to be
approximately $23.4 million compared to $21.4 million for the nine-month period ended December&nbsp;31, 2010. Operating expenses for the nine-month fiscal period ended December&nbsp;31, 2011 are anticipated to be in the range of $25.0 to $25.6
million compared to $19.7 million for the nine-month period ended December&nbsp;31, 2010. Net loss for the nine-month fiscal period ended December&nbsp;31, 2011, before accounting for any anticipated gain on bargain purchase but including the $2.7
million in one-time expenditures noted above, is expected to be in the range of $1.4 to $1.9 million, compared to net income of $2.0 million for the nine-month period ended December&nbsp;31, 2010. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and marketable securities as of December&nbsp;31, 2011 are expected to be approximately $36.0 million compared to $61.5 million as
of March&nbsp;31, 2011. The decrease is primarily due to the Company&#146;s December&nbsp;20, 2011 acquisition of Novozymes Biopharma Sweden AB for $22.7 million (&#128;17 million) in an all cash transaction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The events of this past quarter were exceptionally positive for Repligen, highlighted by our strategic acquisition of Novozymes Biopharma Sweden AB
and the submission of the Company&#146;s first NDA for the potential approval of SecreFlo&#153; for pancreatic imaging,&#148; said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. &#147;I believe that these achievements
position the organization for sustainable growth moving forward.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Herlihy continued, &#147;Looking forward to 2012, we expect
the addition of Repligen Sweden AB to approximately double our bioprocessing revenues. Our bioprocessing business will be further enhanced by the commercial launch in February of a new, expanded line of pre-packed Opus&#153; chromatography columns.
In the area of diagnostic imaging, the acceptance for filing of our SecreFlo&#153; NDA with priority review represents a critical first step towards our goal of building an imaging franchise.&#148; </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Update </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bioprocessing Business Integration and Diversification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective December&nbsp;20, 2011, we completed the acquisition of Novozymes Biopharma Sweden AB, advancing toward our goal of transitioning from a development stage company to an integrated, commercially
focused organization. The acquisition elevates Repligen to a world-leading supplier of products for manufacturing biologic drugs. We expect bioprocessing revenues for the combined company be approximately $37 to $39 million and total revenues to
reach $50 million for the twelve-month fiscal year ending December&nbsp;31, 2012. We are in the process of integrating Repligen Sweden AB personnel and operations with Repligen&#146;s U.S. operations and expect to realize overall operational
efficiencies and economies in the second half of 2012 as a result of our combined efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen&#146;s bioprocessing business delivers
high value consumables to the biologics and monoclonal antibody markets. In addition to providing Protein A and growth factors to these markets, we can benefit from rising market demand for single-use biomanufacturing technologies, which can reduce
operating expenses by decreasing production time and increasing GMP facility flexibility. We have responded to customers&#146; requests by developing a new line of pre-packed, &#147;plug-and-play&#148; chromatography columns under our current
Opus&#153; brand. In February 2012, we plan to commercially launch these larger-scale Opus&#153; products that are suitable for the production of clinical trial material </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended
Dec. 31, 2011 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I> Page
 3
 of 5 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and niche commercial products such as orphan biologics. We estimate the total chromatography market for clinical stage biologics to be approximately $100 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SecreFlo&#153; for Pancreatic Imaging </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As announced this morning in an accompanying press release, Repligen has received notification from the U.S. Food and Drug Administration (FDA) that our
SecreFlo&#153; NDA, submitted on December&nbsp;21, 2011, has been accepted for filing with Priority Review designation. Under the Prescription Drug User Fee Act (PDUFA), the FDA&#146;s goal for completing a Priority Review and delivering a decision
on marketing approval is reduced to six months compared to ten months for a Standard Review. The FDA has assigned a PDUFA goal date of June&nbsp;21, 2012 to the SecreFlo&#153; NDA. Priority review of the NDA for SecreFlo&#153; is based on the
FDA&#146;s recognition of the need for safer, noninvasive alternatives to the diagnostic use of endoscopic retrograde cholangiopancreatography (ERCP), a potentially harmful endoscopic procedure used to evaluate abnormalities of the pancreas.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SecreFlo&#153; was previously granted Fast Track designation by the FDA and also has Orphan Drug status, which qualifies Repligen to receive
seven years of U.S. marketing exclusivity for SecreFlo&#153;, if approved. The Company is also planning to file a marketing authorization application (MAA) for SecreFlo&#153; in the EU during the first quarter of 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our SecreFlo&#153; NDA was submitted to the FDA based on positive outcomes from the re-read of our Phase 3 clinical study, as detailed in the
aforementioned press release titled &#147;<I>Repligen Announces FDA Grant of Priority Review for SecreFlo&#153; NDA</I>&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contingent on
FDA approval, we plan to employ a targeted sales force to market SecreFlo&#153; in the U.S. and to identify marketing partners and distributors for territories outside of the U.S. We estimate the market opportunity for SecreFlo&#153; in the U.S. and
EU to be approximately $100 million for the initial pancreatitis indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A pilot study is currently being conducted to evaluate the
ability of SecreFlo&#153; to improve the detection and characterization of pancreatic cancer in combination with contrast-enhanced MRI and computed tomography (CT). Early detection of pancreatic cancer can increase identification of patients who are
candidates for surgery and may improve patient outcomes. We expect to report initial results from this study during the first half of 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Orphan CNS Drugs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing two
central nervous system (CNS) therapies, RG3039 and RG2833, for Spinal Muscular Atrophy (SMA) and Friedreich&#146;s ataxia (FA), respectively. Both SMA and FA are serious and debilitating neurodegenerative diseases typically diagnosed in childhood
and each is characterized by a defect in a single gene that results in diminished production of a key protein. RG3039 is currently in a Phase 1 study involving healthy volunteers, with no serious adverse events reported to date. We are also
preparing to initiate Phase 1 studies of RG2833 in patients with FA. There are approximately 20,000 patients in the U.S. and Europe with SMA and 15,000 patients with FA worldwide, a combined market opportunity of greater than $1 billion. We are
currently engaged in partnering discussions with companies that could accelerate the global development of our CNS programs as we focus on near-term commercial opportunities within our bioprocessing and diagnostic imaging businesses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended
Dec. 31, 2011 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I> Page
 4
 of 5 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Change in Fiscal Year </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have implemented a change to our financial reporting periods to make our fiscal year consistent with the calendar year moving forward. Historically, our fiscal year end has been March&nbsp;31 and it
will be December&nbsp;31 beginning with the year ended December&nbsp;31, 2011. This change allows for more standard marketplace assessment of Repligen&#146;s business performance. The Company&#146;s fiscal quarters will now end on the last days of
March, June, September and December. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen will report audited financial results for the nine-month transitional fiscal year (April 1,
2011 &#150; December 31, 2011) in March 2012. The Transitional Annual Report on Form 10-KT will include applicable Repligen Sweden AB financial data for the December&nbsp;21 &#150; 31, 2011 post-acquisition period. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Meeting of Stockholders </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen&#146;s Annual Meeting of Stockholders will be held on Thursday, May&nbsp;24, 2012 at Repligen&#146;s corporate headquarters in Waltham, MA.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Walter&nbsp;C. Herlihy, President and Chief Executive Officer of Repligen will host a conference call and webcast today, Tuesday,
February&nbsp;21 at 10 a.m. EST to discuss the financial results for the quarter and nine-month fiscal year ended December&nbsp;31, 2011 and business updates. This call is being webcast by Thomson/CCBN and can be accessed via Repligen&#146;s website
at www.repligen.com. If you are unable to access the webcast, you may listen live by calling <B>800.659.2037</B> for domestic calls and <B>617.614.2713</B> for international calls. Participants must provide the following passcode: <B>95366975</B>.
For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call on Repligen&#146;s website www.repligen.com. You may also access the audio archive by dialing <B>888.286.8010</B>
for domestic calls and <B>617.801.6888</B> for international calls and provide the following passcode: <B>84021465</B>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Repligen
Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also
applies its expertise in biologic product development to SecreFlo&#153;, a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the company has two central nervous system
(CNS) rare disease programs in Phase 1 clinical trials. Repligen&#146;s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at www.repligen.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act
of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press
release which are not strictly historical statements, including, without limitation, express or implied statements regarding future financial performance and position, synergies and revenue growth following Repligen&#146;s acquisition of Novozymes
Biopharma Sweden AB, Food and Drug Administration approval of RG1068, the possibility of seeking a collaboration partner for RG1068, RG3039 or RG2833, management&#146;s strategy, plans and objectives for future operations, including the ability to
increase revenue and expand the business through acquisition(s) and/or collaboration(s), plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for
regulatory approval, litigation, intellectual property protection, product development, manufacturing plans and performance, projected changes in the size of our markets, our market share and product sales and other statements identified by words
like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships; the integration
and performance of Repligen Sweden AB; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation
of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended
Dec. 31, 2011</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I> Page
 5
 of 5 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration
regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on
third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen&#146;s annual report on Form 10-K on file with the Securities and Exchange
Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking
statements reflect management&#146;s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by
law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # #
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g304783ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g304783ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`'@")`P$1``(1`0,1`?_$`&T```(#``,!````````
M```````(!PD*`P8+!0$!`````````````````````!````8"`00"``0&`P``
M`````@,$!08'`0@)`!$3"A(4(3$5%C)2(R24%]57&!$!````````````````
M`````/_:``P#`0`"$0,1`#\`9_W9;Y2Q?3;4S7))(%B!]N'81[LY<QH3%Q1;
MW#:4@;@RKRWHQ+V1F-B>5V\SJ"4JH790K3`/*`(:,0R@7&@/2XIVS->Z6L2P
M]Q;AA-GV#3U>36:Q5JKB'.<?A\XED,:'V01U`-Q<&YV<VJ./C@:E+&=]90H*
M)P(6"A"R$(5N<<Z?<+AM]ARNN,^'7[,[HK'_`'-#*ALF&Q]>>P5A/Z\NZNHS
M9/[].K*325\C\2DM?,\L2/ZLU"J,=R3FE6C3J5(%)I"H/3NDDGC4.9ETCE\A
M8XK'FPK)[D_21V0,;,WDX_,Y<Z.:A*A2%8_F,&''01K56QVO5[Y<<4??%,W+
MEG/6I7?%56A"+#RUJFU<:V.*9Q_:+X\?1/0.1`TYX#?B(H\`BQ8P/&<=!V":
M7#4E;+VMJL2TJY@+H]EB-96V:3>,Q9>[E`."F&8UHWQS0J%Y85`PEYR4$>,#
MS@/YY[=!'\XVZU0K&=LE6V3L]KS7MG250>DCE<SBZ:VB<[?U24!1BI,R1!^D
MJ"0.JA,6>`1@"$Y@@8&'.<8QG'03LX.S:U-2Y\<%A"9H;6]2[+7`8ODF3MJ-
M,-8I6"&7@?R(*2EB'G(>_<./P[]!Y\GJ;MQ.V'*_RA\@BTES)&M;YF[(V]R`
MC^PC=]P+Z?K.PJ<A)LJ"P/*)KJY:FS@D[).<*COX\?'.`L_U[TFT9V4]BJT>
M02O^32%7Y?\`6;E-Y9(-+XA3:Y"[5Y_KVJV74HPV4VJJG[FD<6RNE[@A"(13
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MYO;ZXHVAH;DV!!!E0O<G`Y.C1D8&/&/F8,(>^<8[_CT$/TYM)K+L28^DZ_;%
MT3>AT66&MTF*IRW:_LXR.N!'B\R%]!"9"]B:%A/F!\BE&"QA^8>^/QQT$NJY
M''D#LW,"Y^943Z[@,&TLJMT0IG9T`2$8CAMS<<>!8M`4$L619*`+`<!SW_+/
M00JT;;:J2"V%%"L.S6OCW>:,DU2KI=HN>N'*V$J<@PHD\]172*2'3`@DDX\`
M!C$CP$(AAQG/?..@8/H/,[]P2?3:_P#E4UKU4@$1D5D+ZWH2%ML=KVO6ERD-
MB2NS;MGLB<W2.QYJ9D+ZX+WA[C+)&R6Y(0W*%/G$(>`'8-`6$'XLGV/>=6JJ
MJE,F=N#6>4W%83%%BQ38EFZ^[B)*Z@#.S(,YR_2Q2[1^'H28^RI"/(>(]U0E
MA+!G(C@8QG/0?!]8VGZRWZVYVCYGMH[]:[2W`KZ1.B^0U(5"U,5C=%K;/990
MPL%GKGE8=EK>4!U91%S9HTC1`$F9$*8\2DX]:62),%3ET\CVK?,]R4SF0\I.
MY]@:Q\9=0N;ZXZ\T[`8K;LI634II=2H]$\$M4`J6>!CLHG#`)6[R%_>6\#DB
M3J?TEN$6$>#4H+CM!-^/C3;D1TWOK@*V$M&U0))-'U,B@3RGMR`.#7-R)FTM
MA-=DS&Y*Z@*]XAESQQU-;%I)Y3FF3%A/^R8(LX!>`N+YRXM*.3OV6]4=`*TM
M"00<ZJ(;5\*<Y3&\*6YYJV0A9Y5M99LVAKH2`@XV8-=2G-2E(I*.R4G<&\DO
M.2S"3NP,#[!_`/QN:<<8=F[5T-#[`A^PM832JU+C8DGN>R[">;O66-9L>@TM
M+L!MGK])H\8[K2)<H?!*69(R'96(,9$,1(C2#083C[VVLFH?4+M.\)W-U*1\
M@E'[/4[2DN>50E*UI3/,[D=&TPW(3%S>`DTR,S22$-;0GSE80`M(F(R+X!R0
M4!ZGD<;-3.&;;?=.=#9VMIDEC73;1CN:(!>`5;KC5;>B\[VM-*(R2!%*VB3Y
MP5\C"BB,X,P+`SC``!=?2HK663)ZY&=QYTN"]O$ZD]9UJ5(560F/;Q+%JN:V
MG:ZYQR%,240%<J?X\?CQ"S@\X9GR`#!1>1@]GK/G-^V6R',)RBR)W)FLOO7;
MQQI2O)*>A;2S8_3,!2@E<:8V(\@@"Y.T+87)XFA&`8L^8B.(Q&",."89D+G-
M_=D>4&DYK`F;0CCBCFZT/>(LN<Y[,9%L_4%!@ALE+=C$C=&D+38,D;'>0"4M
M9?VC5!2?"8K`P`P8,>1A+!*N-_ETW:VOY#KPT`VHT/@NJLPUUIA-:EKN$<V%
M8+P41YTDI]?F5_#3UD%1+8=ATE;#/,.>,`=#CDZ9&8`PH)G?`0H+L_E+XN^1
M;?W9!VY:=N7V):/ZOV8KJ[3S2B+1+91\KF[5D/=AIY!LW=3YKY"Y(VS(#X],
MV!L+8L7EX);U'A&0$D!XW,(SV8V2X2&?=[B\O'@TG#57^TY&[5'U#;$)J.I-
MA*@@DVU[L)_$P2@B3QJS:[A4%<E2]<N)9U'Z<,MS7I'<8C\&_43')`L]W*I2
M5\G'LTPO7MIMVP*YIK0W1P+W=#Q5*S+#+$"NYE"[$PKICL1(3ETKB5W;`;?C
M[:M6(5!#MB+(EV6\1!V3%(`@[V1.*S0_4;2O6>8Z1:\LNONVIVW](5!KO)*4
M6N<8G$NE4A:Y>N1,\BE*ET,6KW%.HC9#DC?5BPES1O*-*(*\`3CBSPV1?M.Z
M?^P&O_%#_P`-T&`32LLG?GW$;XN0C!AD7H&U+XE:H*\HAP&YM.M->I]580XH
MS0B&2D2G2XED<4HQ8$,M,``.P#<X$`-IG,/9JRG^*[D$GS:H*2.K=J;=3.SJ
MSD^58$CU,H4Z0MF58393+"3S4SI(2A@"<6-/D8<>;^E\\X#+%Z<E#L4UT`Y,
M'9C?$[38MYSQ%0[DJRO4#.8F*+TJ\J8*^'MI)PQHTX7V[7L0#RR@F*,IAA^0
M_`'``JPXPKWG_`[96RVLO(QQ06!?""<3>.DPV:,]0LTS=$LZCJ9S:B&VOW^;
M1E3#[&@%BM"].L1*6ET3GIC$F<^!7E2(*(-*/%I/-^]^=G7>YK$XN=/]$^.Y
M@7G.T%2VKK(47M5.%"!']2/M<.>G%7#RTPL2-+AV7R$Z)IFY.ER%"W_</[K2
M0RTZZ[A;3KN;G>3F#UHI5RVXK:@[SL!1:,"J[SN#[+-9;9>991-;.,2&U1V6
M."S]%B+,U.F7!&GSCNWX//P%O&KR6%@.Z>Y/(#[0C[3>E^G&H%I:X:E-D^Q/
M+=N2T37H<3<'*+JE<5_4)[*VQG9X>%DKM8M<!)XJC4N[H[/90#<`+,;\9(!]
M/9?BD$XY.`[6/C\J'R*(J\6?35*A6.`D:)W?8]5S%)K<F$\=DS8C3(%<AEMG
M1EN7N6"BB"1+'4TW&,=@@R';[Y)SQZ>GA'(:C8%$<EEHZI5G&G%@>1K$#N7)
M]UI\URJSBG4I<4)Q3N[;'[2>S1(30!&FREPDS@H!?8`.AZEM"E4UPXU?,#V)
M6R/NQUL7#=KSEQ*6$KG%.5)0U'%W'!"X(#$S4XQ&JD*I%@K&$RA.HPK+^7V1
M&#"MRB;1MGUBMK=QJLO+6&X+1XL]E[:=MA:1V`USKLF1-U$*G=:0VJ(G/FLM
M<TL#(UQJ'C1-J\DY<B5>./DK6M&I*6&ITX6J`Y^T>V305$.)7339O<RTY8`Q
M%%[,FU9/5':AP,\+DUM3E)+7N6:G-RHMMC(URDT;:VHC5;D>VFI"SDXC"C^@
M7'UU]0-FX!<7,[>6Y"^8O%]6_M^_T0XV5(8M(HTR6"AIQ7.CG*S*J22=$@7*
MJOE2RQTP6+ZQ@VTAK:TB9+D`",AP".\4.\-2<%5569QN\I=$7%5$SK[8B<J*
M7O-NH:5V95^Q\=G*AN.91U\]QAD?%"QS4?4^TG3I\JBQ)50"3!DKR%*4`7C:
M4[$;?;[;4G79%=<774'C/@,97-D01;`4W&XMLAM/9/VU)22:,T==$RM[JFJ&
M?Y!.3G"SE4YA(*R6,`CSP)`57@!._P#0NXG.5O\`*AA4EVYO9G6R&')C2E#8
M7!M861:C8%"-424`*I4\Q*<L(U(L"&#^W+R#M@0A##CY>NVR_--P5:.E*!.+
M!";'LS>NTX\W'9-4HD=--^'ZHY!)"2\#PU1I=(*PD#44:?@):\]68E+%Y>P1
M!J'Z`Z`Z`Z`Z!?-M'>SV#5K8]ZI*)GSNY&NB[76U3#4SHW,9LFL8B#/@X6S8
M>'9<VM[6!=(L)P#/,/+P4#.18S\L8QD,:/H^HJC+IW?IQ;7E.??"JRZ5132/
MC2O(%394;?%IJ?6+RF6JD@(\H3OLR<I<0>4A/,6DB;BA+BRRC6X1H;L>@.@.
1@.@.@.@.@.@.@.@.@.@__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
